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ABSTRACT
Objectives: With the advent of ongoing novel modalities toward the treatment of human epidermal growth factor receptor 2 (HER2)/NEU - positive 
malignancies, the serious side effects of chemoradiotherapy have been minimized. Hence, this study was conducted to identify the patterns of 
immunohistochemical expression of the promising therapeutic target (HER2/NEU) among Iraqi patients with medulloblastoma in an attempt to 
provide basic histological information’s that would help in future clinical researches.
Materials and Methods: In this retrospective study, 42 formalin - fixed paraffin - embedded tissue blocks represent cases of surgically removed 
medulloblastomas were retrieved from the archived materials in a specialized surgical hospital at Bagdad. The histological diagnosis had been revised, 
and all cases were stained by the immunohistochemical technique with HER2/NEU antibody and assessed independently by three pathologists.
Results: Out of 42 cases, only two which represent 4.76% showed positive results manifested by a strong membranous staining when 
immunohistochemically evaluated using the same scoring system established for HER2/NEU in breast cancer. 14 cases (33.3%) showed incomplete 
membranous and five cases (11.9%) showed only cytoplasmic reaction patterns.
Conclusion: The rate of expression of HER2/NEU in medulloblastoma among Iraqi patients is very low and found only in aggressive anaplastic histological 
type when immunohistochemically evaluated using the same scoring system established for HER2/NEU in breast cancer. However, a good number of 
negative cases showed cytoplasmic and incomplete membranous staining patterns highlighting the importance of establishing medulloblastoma - specific 
HER2/NEU scoring criteria and testing methods to discover the unique feature of expression of this therapeutic target in medulloblastoma.
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INTRODUCTION
Medulloblastoma is the most common malignant tumor of the central 
nervous system in children [1] in which it constitutes about 20% 
of all intracranial tumors and 40% of all childhood posterior fossa 
tumors [2], it is highly invasive pediatric brain tumor with fast cellular 
proliferation that commonly disseminated throughout the central 
nervous system at presentation [3]. According to the recent World 
Health Organization (WHO), medulloblastomas are grouped based 
on molecular features in addition to histopathological characteristics 
for more accurate assessment of risk in children, this molecular 
classification relates to the clustering of medulloblastomas into groups 
on the basis of transcriptome or methylome profiling [4]. The major 
histological subtypes of medulloblastoma are classic, desmoplastic/
nodular medulloblastoma, medulloblastoma with extensive nodularity, 
and large cell or anaplastic medulloblastomas, each has their own 
particular clinical associations [5-8], a distinct morphology, age of 
onset, and prognosis [9]. Irrespective of their histological or genetic 
features, medulloblastomas are considered as Grade IX according to 
(WHO) grading system which is regarded as the highest histological 
grade [10].
HER2/NEU oncogene is a member of the tyrosine kinase family 
similar to the epidermal growth factor receptor (EGFR), it is located 
on chromosome 17q21 and encodes a 185 kd transmembrane protein 
that lacks a natural legend [11]. HER-2 activation starts off signal 
cascades including the MAPK and PI3K/AKT pathways in which they 
are necessary for cell proliferation and differentiation [12]. Overactivity 
of EGFR signaling leads to uncontrolled cellular proliferation and 
increased survival which leads to cellular transformation and tumor 
progression [11]. Medulloblastoma has been reported in the literature 
to have an overexpression of HER2/NEU in contrast to normal cerebellar 
tissue [13,14]. The successful story of anti-HER2/NEU (trastuzumab) 
in the treatment of advanced metastatic breast cancer has not only led 
scientists in developing newer molecules and targets against HER-2 but 
also has been tried as a therapeutic option in other malignancies [15]. 
Although HER2/NEU expression in medulloblastoma approved to be 
relatively lower than in breast cancer rendering monoclonal antibodies 
may be ineffective, a recent study suggests new modality about adoptive 
transfer of HER2-specific T cells in a promising immunotherapeutic 
approach for medulloblastoma [16]. To identify new targeting drug 
delivery systems for malignancy, cancer cell biology needs to be 
extensively understood [17]. Furthermore, there is an urgent need 
for novel therapy in very young child with medulloblastoma that 
improves dangerous toxicity so this study was conducted to identify 
the patterns of immunohistochemical expression of human epidermal 
growth factor receptor (HER2/NEU) in the most common pediatric 
intracranial malignancy (medulloblastoma) in an attempt to provide 
basic histological information that would help in future researches.
METHODS
In this retrospective study covering the period from January 2014 to 
November 2017, 42 formalin - fixed paraffin - embedded tissue blocks 
with initial diagnosis of medulloblastoma were collected from the 
archived materials in the Histopathology Department of Gazy Al Hariri 
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teaching hospital for surgical specialization at Bagdad, the paraffin 
blocks represented all cases of surgically removed posterior fossa 
medulloblastomas in at that period. Clinicopathological parameters 
such as age, gender of patient, and histological/morphological types 
were obtained from the available histopathologic reports.
Two sections of 5 Mm thickness were taken from each block; the first 
was stained by hematoxylin and eosin (H and E) for histopathologic 
revision, the other section put in a positively charged slide and stained 
immunohistochemical for HER2/NEU.
The H and E stained sections were reassessed for the morphological types 
of the tumor by three independent pathologists. For detection of HER2/
NEU antigen, we used polyclonal rabbit antihuman c-erb-2 oncoprotien 
(Code A0485) manufactured by DAKO with a dilution of 1:1000, sections 
from the breast carcinomas that known to be immunoreactive for 
HER2/NEU were used as a positive control, while the negative control 
slides were obtained by omitting the primary antibody. All sections were 
stained at the governmental hospital using autostainer equipment (X 
biogenex i6000). To perform immunohistochemical staining bimanually 
on each block, 5 mm sections were made and applied the section on a 
positive charge dewaxing paraffin-embedded sections. After antigen 
retrieval was performed, the tissue sections were covered with peroxide 
block solution for 5 min followed by incubation of primary antibody for 
30 min, then the tissue sections covered with poly excel poly HRP and 
incubate for 30 min at room temperature, working solution and incubate 
for 5 min at room temperature, and finally hematoxyline stain was 
applied. Immunohistochemically stained sections were evaluated under 
a light microscope(leica DM500) independently by three pathologists 
by using the same scoring system established to evaluate HER2/NEU in 
breast cancer [18].
Score 0 no staining or membranous staining is observed in <10% of the 
tumor cells.
Score 1 + partial faint membrane staining in more than 10% of the 
tumor cells.
Score 2+ circumferential weak to moderate membrane staining 
observed in more than 10% of the tumor cells.
Score 3+ circumferential strong membrane staining observed in more 
than 10% of the tumor cells. Scores of 2+ and 3+ were considered 
positive for HER2/NEU.
Photomicrographs were taken in this study with a camera (Leica Icc 
50E).
This retrospective study was approved by the ethical committee of the 
national center for educational laboratories and done in accordance 
with it is an institutional policy in which patient consent was taken at 
the beginning of consultation for any future studies.
Statistical analysis
Satistial analysis was performed with SPSS versus 25.
RESULTS
A total of 42 tissue samples representing medulloblastomas were 
included in this retrospective study. The mean age of patients with 
medulloblastoma was 7.53 years, with age range of 1–22 years. The 
distribution of medulloblastoma cases according to age groups was 
shown in Table 1.
The present study showed that 27/42 (64.28%) of cases were males 
and 15/42 (35.71%) were females, with a male to female ratio was 
1.8:1.
Regarding histological types, the present study showed that classic 
medulloblastoma was 31/42 representing 73.80% (Fig. 1), nodular/
desmoplastic medulloblastoma was 6/42 (14.28%), medulloblastoma 
with extensive nodularity was 3/42 (7.14%), and only 2/42 (4.76%) 
were large cell/anaplastic medulloblastoma (Table 2).
After immunohistochemical search for HER2/NEU in 42 cases, 
only two cases showed positive membranous staining scored as +3 
(Figs. 2 and 3) both were of anaplastic morphology. Of 40 negative 
cases, 5 cases showed only cytoplasmic reactivity, 2 showed positive 
nuclear reactivity, and 14 cases showed incomplete membranous 
staining (Fig. 4). According to the scoring system used in this study, only 
two cases (represent 4.76%) were positive for HER2/NEU antibody.
DISCUSSION
This study is not a large epidemiological study that expresses the 
prevalence and incidence of different clinicopathologic features of 
medulloblastoma. However, in general, the overall mean age in the present 
study was 7.47 years, and it was relatively uncommon in adults, these 
findings agreed with the studies of Chan et al. and Kumar et al. [19,20] 
which also found that it was more common in children at their first 
decade of life. Regarding gender in this study a male predominance was 
found, with a male to female ratio 1.8:1, this results agreed with the 
studies of Curran et al. and Herms et al. [21,22]. Histological examination 
of medulloblastoma in the present study showed a clear predominance 
of classic morphology which was in agreement with the studies done by 
Kumar et al., Massimino et al., and Nam et al. [6,20,23].
Table 1: Distribution of medulloblastoma cases according to age 
groups of patients





Fig. 1: (×100) Hematoxylin and eosin stained histological section 
for 5-year-old child with a classic medulloblastoma demonstrates 
small round blue cells morphology
Table 2: Distribution of medulloblastoma cases according to 
histologic types
Histologic types of medulloblastoma Frequency (%)
Classic medulloblastoma 31 (73.80)
Desmoplastic/nodular medulloblastoma 6 (14.28)
Medulloblastoma with extensive nodularity 3 (7.14)
Anaplastic medulloblastoma 2 (4.76)
Total 42 (100)
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searching for this purpose in an attempt not only to give an impression 
on the prognosis but also to help in identifying which patient would 
benefit from the application of the promising targeted therapy based 
on the ongoing clinical trials. The study revealed that only two cases 
(represent 4.76%) showed positive strong membranous expression 
of this marker, this result is relatively low compared to previous 
similar studies worldwide [13,14,23,24]. However, there are some 
discrepancies in the reporting rate of HER2/NEU immunoreactivity in 
the literature and most of the reference texts due to the morphological 
characteristic of medulloblastoma cells, which have a scarce cytoplasm, 
making a difficulty in ascribing the immunohistochemical staining 
whither to the membrane or to the cytoplasm [13]. To improve a better 
quality of results, the process of staining of all samples was done in two 
different sites, in governmental hospital using an autostainer and in the 
private lab bimanually, positive and negative controls were included 
in each run. A number of reasons should be discussed that hopefully 
explain a low expression rate of HER2/NEU obtained in this study. 
Despite developing ideas and clinical researches about the probable 
use of anti-HER2/NEU drugs in medulloblastoma; unfortunately,there 
is no well-established standardized criteria currently available for the 
immunohistochemical methods (ie, tissue handling/fixation, antibodies 
used, controls, and artifacts) and for interpretation and scoring of HER2 
immunohistochemical results in medulloblastoma util now unlike in 
breast cancer and this issue is problematic because the most important 
factor predict patient response to targeted therapy is an accurate and 
reliable searching test. On the other hand, this study used the same 
scoring system established for breast cancer and it probably may not be 
suitable for other cancer with HER2/NEU expression, this fact approved 
by a recent large international clinical trial on the use of targeted anti-
HER2/NEU therapy in gastric cancer (Trastuzumab for Gastric Cancer) 
in which the positivity (therefore the benefit from targeted therapy) 
was accepted as cytoplasmic and incomplete membranous staining 
patterns [25]. Accordingly, the interpretation guidelines in biologically 
and pathogenetically different tumor types could not be simply applied 
because this result in unreliable immunohistochemical interpretation 
so the specific scoring system should be urgently established. 
To reach this purpose, it’s important to illustrate the pattern of 
immunohistochemical staining in both positive and negative cases, in 
this study 14/42 (33.3%) showed incomplete membranous staining 
and 5/42 (11.9%) showed only cytoplasmic reactivity. Although 
cytoplasmic or incomplete membranous staining has been considered 
unspecific or art factual, therefore according to the above explanation 
they should be investigated for targeted therapy response. Although 
this new era brings promise, the limited numbers of medulloblastoma 
cases often remain a major work impediments.
Furthermore, the complex issue of intratumoral heterogeneity regarding 
HER2/NEU over expression and amplification which is already present 
in a subset of breast cancer cases both at inter and intratumoral level is 
regarded by most authors as an unavoidable factor for accurate HER2 
status assessment [26,27]. From this point of view, low expression rates 
in this study may reflect a high intratumoral heterogeneity for HER2/
NEU expression in medulloblastoma which if it is confirmed will open a 
challenging field of research in future.
Gilbertson et al. had demonstrated in a retrospective study of 55 cases 
of MB, the prognostic value of HER2/NEU expression was dependent 
on the percentage of positive tumor cells [13,14], these observations 
necessitate the development of medulloblastoma - specific HER2 
histological scoring criteria and immunohistochemical testing methods. 
Because this is the first Iraqi study, as a starting point we thought we 
should stick to the scoring criteria of the original HER2/NEU scoring in 
breast cancer (established by more than 10 years experience in HER2/
NEU overexpression study and clinical correlation with treatment 
response) aspiring that it becomes a basic template for more future 
studies about the overexpression of HER2/NEU in medulloblastoma 
in conjunction with other ancillary tests and correlate them with 
clinical response to targeted therapy to identify the unique features 
of HER2/NEU overexpression in medulloblastoma with the final goal 
Fig. 2: (×100) Immunohistochemically stained section of 
medulloblastoma with human epidermal growth factor receptor 
2/NEU antibody demonstrates strong positive membranous 
staining in more than 10% of tumor cells
Fig. 4: (×400) Immunohistochemical stained section of 
medulloblastoma with human epidermal growth factor receptor 
2/NEU antibody demonstrates the negative result (only 
cytoplasmic staining pattern)
Fig. 3: (x 400) Immunohistochemically stained section of 
medulloblastoma with human epidermal growth factor receptor 
2/NEU antibody demonstrates strong positive membranous 
staining in more than 10% of tumor cells
There are few studies worldwide focused on the overexpression of HER2/
NEU in medulloblastoma, the present study is the first study in Iraq 
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of establishing medulloblastoma - specific HER2 histological scoring 
criteria and immunohistochemical testing methods to standardize 
immunohistochemistry for this application.
CONCLUSION
The rate of expression of HER2/NEU in medulloblastoma among 
Iraqi children is very low and found only in aggressive anaplastic 
histological type when immunohistochemically evaluated using the 
same scoring system established for HER2/NEU in breast cancer. 
However, a good number of negative cases showed cytoplasmic and 
incomplete membranous staining patterns highlighting the importance 
of establishing medulloblastoma - specific HER2 scoring criteria and 
testing methods to discover the unique feature of expression of this 
therapeutic target in medulloblastoma.
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